ACCME (CME)AACN (CE)ACPE (CE)Programs by TopicUpcoming Events & RegistrationResources

Advancing Today’s Knowledge on Gaucher Disease

  1. Andersson HC, Charrow J, Kaplan P, Kolodny EH, Mistry PK, Pastores GM. Consensus statement by the ICGG U.S. Regional Coordinators on individualization of enzyme replacement therapy (ERT) for type 1 Gaucher Disease. Available at: http://www.GaucherRegistry.com. Accessed June 11, 2007.
  2. de Fost M, Vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. Jan-Feb 2006;36(1):53-58.
  3. Lee RE. The pathology of Gaucher disease. Prog Clin Biol Res. 1982;95:177-217.
  4. Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, Prins M, Aerts H, Poll R. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis. Feb 2000;23(1):77-82.
  5. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among Hematologists-Oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. May 9 2007. DOI 10.1002/ajh.20908.
  6. Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. Jun 15 2005;105(12):4569-4572.
  7. Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. Oct 2004;41(4 Suppl 5):15-22.
  8. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. Aug 1 2002;113(2):112-119.
  
HomeAbout Us/Contact UsSite MapPrivacy PolicyFAQs
Copyright © 2010 Oncology Today, LP. All rights reserved.